Mechanisms behind tumor suppressor BAP1 highlight new treatment strategies for aggressive cancers

A team of scientists led by the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School (Duke-NUS) has found a ...
Pharmabiz

US FDA clears Lantern Pharma and Starlight Therapeutics’ IND for a planned phase 1 paediatric CNS cancer trial of STAR-001

US FDA clears Lantern Pharma and Starlight Therapeutics’ IND for a planned phase 1 paediatric CNS cancer trial of STAR-001: Dallas Monday, March 30, 2026, 14:00 Hrs [IST] Lanter ...
TMCnet

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today ...
EurekAlert!

Study uncovers the mechanisms behind tumour suppressor BAP1 protein, highlighting new treatment strategies for aggressive cancers

Tumour suppressor BAP1 protein is implicated in several aggressive cancers, but the mechanisms behind it are not well understood. Scientists from the National Cancer Centre Singapore (NCCS) and ...
Fierce Biotech

Drug combo treats multiple cancers with ‘paradox’ mutation in mice

Carbone called BAP1 a “paradox” because of its seeming ability to both promote and slow cancer, depending on the ...

Lantern receives FDA clearance for paediatric STAR-001 CNS trial

STAR-001 is identified for CNS indications by Lantern’s RADR AI platform. Credit: MY STOCKERS / Shutterstock.com. (MY ...
eLife

UV irradiation alters TFAM binding specificity and compaction of DNA

Independent experimental approaches demonstrate changes in TFAM binding to UVC-irradiated DNA, providing a potential mechanism for DNA damage sensing in the mitochondria.
Morning Overview on MSN

Study: Inflammation overwhelms DNA repair in some neurons in multiple sclerosis

Researchers have identified a specific class of brain neurons that dies during multiple sclerosis because inflammation ...

AirSculpt Technologies Q4 Earnings Call Highlights

AirSculpt Technologies (NASDAQ:AIRS) reported fourth-quarter and full-year 2025 results while outlining initiatives ...
Wonderwall on MSN

Bindi Irwin says she was ‘trapped in my own body’ while discussing agony of ‘invisible disease’

Bindi Irwin has courageously shared details of her battle with an invisible illness in a new Instagram post aimed at raising ...

Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

Q4 2025 Earnings Call March 30, 2026 4:30 PM EDTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid Margrave ...

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative ...

Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical research evaluating the effects of PV-10 in a clinically ...